BioSpace News Archive

Biom’up HEMOBLASTTM Bellows full pivotal trial results published in Journal of Cardiac Surgery

Article provides full data set of pivotal clinical trial showing that HEMOBLAST Bellows is clinically and statistically superior to control at achieving hemostasis

January 30, 2019
·
5 min read
Pherecydes Pharma reports successful patient treatment with bacteriophages

Phage therapy could offer an alternative treatment method in the fight against antimicrobial resistance

January 30, 2019
·
3 min read
New study shows how vegans, vegetarians and omnivores feel about eating insects

Many non-vegan vegetarians and omnivores are open to including insects in their diet. For vegans, however, that is not an option, a new study from the University of Eastern Finland shows.

January 30, 2019
·
3 min read
Business

Lonza Achieved Another Excellent Full-Year Result in 2018 with 9% Organic Sales Growth and Strong Profitability Driven by Healthcare Businesses

Lonza reported a 9% organic sales, 12% organic CORE EBITDA and 14% organic CORE EBIT growth.

January 30, 2019
·
14 min read
Deals

Changes to the Nomination Committee for Immunicum AB (publ)

Immunicum AB announced the composition of the Nomination Committee on 19 October 2018.

January 30, 2019
·
1 min read
Medtronic Announces Positive Results from the Largest ENB Study to Aid in Lung Cancer Diagnosis, Staging, and Treatment Preparation in a Single Minimally Invasive Procedure

Company Is Committed to Leading Evidence Generation Across the Lung Cancer Care Continuum

January 30, 2019
·
5 min read
Drug Development

A Long Line of Alzheimer’s Failures: Roche Drops Two Drug Trials

Roche announced that it was discontinuing two of its Alzheimer’s Phase III trials, CREAD I and 2, after a pre-planned interim analysis.

January 30, 2019
·
3 min read
·
Mark Terry
Business

As Novartis Eyes Growth in 2019, the Company Will Likely Cut Some Prices

Novartis Chief Executive Officer Vas Narasimhan said 2018 was a year of reimagining for Switzerland-based Novartis. It was a year when the company focused its capital and resourced on developing breakthrough medicines.

January 30, 2019
·
3 min read
·
Alex Keown
Genetown

Is Biogen’s Aducanumab for Alzheimer’s the Holy Grail or Cold Fusion?

Whenever a drug fails an Alzheimer’s clinical trial, analysts, investors and industry watchers immediately turn to look at Biogen. Will the company’s aducanumab be the one? Will it be the drug that will actually break the string of more than 150 drug failures?

January 30, 2019
·
3 min read
·
Mark Terry
Job Trends

ColdQuanta Sponsors Research at University of Wisconsin to Accelerate Neutral Atom Quantum Computer Commercialization

Executive Chairman Tim Day to Present at Photonics West Marketplace Seminar

January 30, 2019
·
3 min read